Management of sexual dysfunction due to antipsychotic drug therapy (Q24197558)

5

0 references

Levente Kriston

3

0 references

author name string

Hannah M Schmidt

1

0 references

Mathias Hagen

2

0 references

Michael M Berner

Cochrane Database of Systematic Reviews

6

0 references

publication date

14 November 2012

0 references

published in

0 references

cites work

Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Low-dose imipramine for thioridazine-induced male orgasmic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sildenafil use in patients with olanzapine-induced erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sexual dysfunction in women using major tranquilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Effects of risperidone on gonadal axis hormones in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Switch to quetiapine in antipsychotic agent-related hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Prolactin levels and adverse events in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Change in sexual dysfunction with aripiprazole: a switching or add-on study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Haloperidol-induced impotence improved by switching to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Psychological and interpersonal dimensions of sexual function and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Burden of phase-specific sexual dysfunction with SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sexuality and schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sexual dysfunction in the United States: prevalence and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sexual dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

The low frequency of reported sexual dysfunction in Asian patients with schizophrenia (2001-2009): low occurrence or ignored side effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Management of sexual dysfunction due to antipsychotic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

A survey of psychosexual arousability in male patients on depot neuroleptic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sexual Dysfunction in First-Episode Schizophrenia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

A Systematic Review of Research on Strategies for the Management of Antipsychotic-Induced Sexual Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

Sexual dysfunction in male schizophrenic patients.

21 January 2018

1 reference

12 December 2020

Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches.

1 reference

12 December 2020

Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients

1 reference

12 December 2020

A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

Mianserin, a 5-HT2a/2c and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors

1 reference

12 December 2020

Sexual dysfunction in patients with schizophrenia on antipsychotic medication

1 reference

12 December 2020

Sexual disorders in nonacute psychiatric outpatients

1 reference

12 December 2020

Sildenafil citrate (Viagra) treatment of sexual dysfunction in a schizophrenic patient

1 reference

12 December 2020

Two additional uses for sildenafil in psychiatric patients

1 reference

12 December 2020

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

1 reference

12 December 2020

A Randomized Open-Label Comparison of the Impact of Aripiprazole Versus Risperidone on Sexual Functioning (RAS Study)

1 reference

12 December 2020

High doses of clorotepin in chronic schizophrenia (preliminary report)

1 reference

12 December 2020

The Arizona Sexual Experience Scale (ASEX): reliability and validity

1 reference

12 December 2020

Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey.

1 reference

12 December 2020

A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

1 reference

12 December 2020

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia

1 reference

12 December 2020

Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients

1 reference

12 December 2020

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

Fluoxetine-induced sexual dysfunction

1 reference

12 December 2020

An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction.

1 reference

12 December 2020

Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence

1 reference

12 December 2020

The risks and benefits of clozapine versus chlorpromazine

1 reference

12 December 2020

Amantadine in the treatment of neuroendocrine side effects of neuroleptics.

1 reference

12 December 2020

Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial

1 reference

12 December 2020

The Relationship between Serum Prolactin Level and Sexual Functioning among Male Outpatients with Schizophrenia or Schizoaffective Disorder: A Randomized Double-Blind Trial of Risperidone vs. Quetiapine

1 reference

12 December 2020

Antidepressant-induced sexual dysfunction

1 reference

12 December 2020

Drug-induced sexual dysfunction and mental health patients' attitude to psychotropic medications

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003546.PUB3

7 January 2021